Allergy Therapeutics plc (LON:AGY) shares crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $12.46 and traded as high as $11.23. Allergy Therapeutics shares last traded at $11.23, with a volume of 57,863 shares traded.
Separately, FinnCap reissued a “corporate” rating on shares of Allergy Therapeutics in a research report on Thursday, July 11th.
The company has a quick ratio of 3.08, a current ratio of 3.74 and a debt-to-equity ratio of 6.20. The firm has a market capitalization of $71.41 million and a P/E ratio of -22.30. The stock has a 50-day moving average of GBX 12.41.
About Allergy Therapeutics (LON:AGY)
Allergy Therapeutics plc engages in the research and development of allergy treatments. It sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees. The company's products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, and Venomil.
Read More: Net Income
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.